Press releaseGlobe Newswire
Humacyte
HUMA · NASDAQ
$0.406+$0.0049 (+1.22%)TodayMarket closed ·
Prev close $0.4011
Latest news
- Press releaseGlobe Newswire
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
- Press releaseGlobe Newswire
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
- Press releaseGlobe Newswire
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
- Press releaseBusiness Wire
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
- Press releaseGlobe Newswire
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
- Press releasePRNewswire
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
- Press releaseGlobe Newswire
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
- Press releaseGlobe Newswire
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
- Press releaseGlobe Newswire
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
- Press releaseBusiness Wire
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
- Press releaseGlobe Newswire
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
- Press releaseGlobe Newswire
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsVandana Singh
Why Is Humacyte Stock Falling Thursday?
- Press releasePRNewswire
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- News
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
- News
Earnings Scheduled For May 13, 2026
- Press releaseBusiness Wire
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
- Press releasePRNewswire
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
- Press releaseBusiness Wire
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
- Press releasePRNewswire
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- News
Earnings Scheduled For March 27, 2026
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- Press releaseGlobe Newswire
Strong Earnings and Biotech Resilience Define the Midweek Momentum
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
Earnings Scheduled For November 12, 2025
- News
Insights Ahead: Humacyte's Quarterly Earnings
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- NewsAvi Kapoor
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Gold Falls 1%; ProKidney Shares Spike Higher
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- News
Exploring Humacyte's Earnings Expectations
- NewsHenry Khederian
Why Humacyte (HUMA) Stock Is Falling Sharply
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsRishabh Mishra
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
- NewsAdam Eckert
Humacyte Shares Plunge After Hours: Here's Why
- Press releaseBusiness Wire
Trestle Bio Announces Research Collaboration with Humacyte
- Press releaseBusiness Wire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- Press releaseBusiness Wire
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
- Press releaseGlobe Newswire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA
- Press releasePRNewswire
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - HUMA
- Press releasePRNewswire
Humacyte, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - HUMA
- Press releasePRNewswire
Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- Press releasePRNewswire
The Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline
- Press releaseBusiness Wire
Deadline Soon: Humacyte, Inc. (HUMA) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.